Member Info for P3T3R

Would be interesting to know, if in all their haste they missed out (or simply skipped) the Quality Certification.

It was always thus. It is always far easier to find fault than to do ... especially given the benefit of hindsight.

ROFLMAO.

Courtesy pedr01, posted only yesterday on the "other" thread;

"Diversification is an idea invented by brokers to get punters to buy stocks they otherwise wouldn’t even consider buying. The logic goes like this, ”Don’t just buy good stocks, buy lots of rubbish as well because it will prevent you from losing too much money.” This may well be the case, but what it is far more effective at is preventing you from making any real money.

Stocks are like eggs, only buy half a dozen and avoid the cracked ones."

Eerie or what ...

Thanks for clarification ... I tend to just pop in and out occasionally ... Added 100k+ for my sister's ISA ...

I would say there is zero chance we are working flat out on covid testing. In the last video he said we were ready and waiting instructions.

Are you ramping flipper ...

Not too sure that is how I would interpret the RNS. As I understand, the forecast was for £16.99m of revenues, of which £16.6m was delivered and £0.4m was delivered but fell into the new reporting year due to transport restrictions surrounding covid disruptions. So, they would have met the forecast £16.99m but for covid disruptions.

The RNS actually states in the first paragraph that "The revenue increase reflects organic growth of approximately 36%; 11 months contribution from Elucigene Diagnostics, acquired on 26 April 2019; and three weeks' contribution from the Company's French NIPT distribution business, acquired on 10 March 2020."

.
.
.
.

I do not read the RNS to mean that £0.4m was covid orders ...which have only just begun

It's obviously a computer auto-generated report to get people to visit the site. Click bait ... Once you've read a few, you get to see regular sentences that pop up all the time.

Any chance of a lead on the general view of the Greidingers ... only just started looking in here ...

Thanks for posting poker ...
There's a video in the public access area ... https://www.buceph.com/public_cineworld.html

Algu

When to sell is always difficult. It's nice to take a profit and hard to admit that we were wrong, but I take the view the you should always ride your winners. I have made plenty of mistakes, some of them quite large, but my winners keep me ahead by a good margin.

You need to do your own research (as opposed to just following tip-sheets) so that you understand why you are buying and the reasons for growth, regularly re-visit your reasons for buying to make sure that the sources of growth are still applicable going forward (or maybe different areas of growth are being nurtured). The share price is driven by growth (or expectations of growth).

Looking back I started buying AMS (which I still hold) at sub-15p in Dec 2006 when they were just starting to go into profitability. They went from 15p to 35p in two years and 90p plus in five years ... And they make bandages and medical dressings ... At the time, the reason for buying into AMS was they were just about to break into the US market with their version of a medical superglue.

So the possibilities here ...

Hopefully I am not teaching you to suck eggs, just trying to provide some words of encouragement. If you keep at it, eventually it will all make sense. It took me a loooooong time before it started to make sense.

Algu ... You need to take a personal view of the future that you are comfortable with. You need to decide what seems sensible for yourself.

At the moment circa 16.75p, taking a two year view, people are paying 56x projected earnings for 2022. Official forecasts are;

2020-03-31 16.99 -0.65 -0.09p 0.0 n/a 0% 0.00p 0.0%
2021-03-31 20.90 0.78 0.10p 144.6 n/a 0% 0.00p 0.0%
2022-03-31 24.73 2.31 0.30p 48.4 0.2 199% 0.00p 0.0%

There are some who view the official forecasts as woefully inadequate and project maybe 50% revenue growth for next few years. Lets say that you feel that +35% for next 3 years is very much do-able given the three pronged growth strategy, so 17m * 1.35 * 1.35 * 1.35 => Revenues of £41.8m for 2023. Forecasts suggest 0.2p eps for every +£4m revenues, so (41.8-17)*.2/4 = 1.24p eps (2023).

So, anywhere between 30x and 56x (because people are always forward looking towards the next year) gives a range between 37p - 69p for 35% revenue growth.

I am not saying that this is my view, but hopefully it gives you a starting point to try to decide on your own viewpoint.

Good luck ...

Remember, they expect to breach £15M+ ...

FORECAST (from digitalLook/Sharecast)
Year Ending Revenue(£m) Pre-tax(£m) EPS P/E PEG EPS Growth Div Yield
2020-03-31 16.99 -0.65 -0.09p 0.0 n/a 0% 0.00p 0.0%
2021-03-31 20.90 0.78 0.10p 144.6 n/a 0% 0.00p 0.0%
2022-03-31 24.73 2.31 0.30p 48.4 0.2 199% 0.00p 0.0%

Pretty sure I read somewhere they expect to achieve the forecast £17m ...

£50m+ would be fantastic, but slightly over-reaching.

I think forecasts on DigitalLook are in region of ~£20m next year rising to £24m (?) the year after. Tried to confirm, but site appears to be down for maintenance.

Obviously I am hoping that you are right, and that the forecasts are erring on the side of caution ...

Honest Tom ... from memory, there was a 15:1 consolidation, and then a further 10:1 consolidation which leaves you with 8.3 shares, rounded down. Might be cheaper to donate your shares to charity than selling.

Does seems like it's done and dusted, Throop moving over to Hasbro ... Have to admit to being slightly disappointed with £5.60.

Hasbro earlier in a statement said "top eOne executives have agreed to join the Hasbro team," without identifying who they might be.

"Along with our leadership team, I look forward to working with Hasbro on our joint growth and success for many years to come," eOne CEO Darren Throop, who will continue to lead the indie studio, said in his own statement.

Https://www.hollywoodreporter.com/news/hasbro-buys-entertainment-one-4-billion-1233917

Https://www.spielwarenmesse.de/toy-market-news/detail/license-global-announces-the-2019-top-150-global-licensors/language/1/

Entertainment One 27th ($2.5b) ... $1.5b in 2018

Provides a nice warm feeling that Peppa Pig and PJ masks going great guns.

"I'm going to do my best Victor Meldrew now and ask that other posters turn up at these events. There was only 4 PIs (maybe 3, I don't know who the 4th was) at the meeting - there is no compulsion for AAU to put these on, if one day only one person (or none!) turns up we may lose them. Grump over."

I did e-mail the company ( info@arianaresources.com) to ask whether a "letter of representation" was needed to attend, with no response. I asked selftrade for a letter anyway, and was sent one for the AGM on the 28th.

I did try.

If you want to attend meetings, you can ask your broker for a "Letter of Representation". Just tell them where, when, etc ...

In hindsight, my only regret is top-slicing and diworsifying over the years ... LOL ... Still plenty in the pot though ...

Efficiency and gross margins We continue to make operational improvements by reducing set up times, eliminating non-value added activities and increasing outputs wherever possible. These incremental efficiencies help to improve gross margins across the Group. The launches of the two new foam dressing ranges have required new converting processes to be developed and the success of the launches has resulted in significant volumes of new product being required. We are pleased that we met these significant volume demands, however, the initial efficiencies of these processes have been lower than for our more established ranges and lower than we would expect to obtain on a regular basis. We estimate that these operating effects have had a negative impact of around 400 basis points on the operating margins for the OEM business, where most of the sales of these products have been recorded. Changes are currently being made to the manufacturing processes to improve our efficiences and we would expect to see margin improvement in 2017.